|
| Press Releases |
|
 |
|
| Monday, December 7, 2020 |
|
|
Sino Biopharm Invests in Sinovac LS, A Leading COVID-19 Vaccine Company in China |
| Sino Biopharmaceutical Limited ("Sino Biopharm" or the "Group"; HKEX: 1177) has announced the investment of US$515 million in Sinovac Life Sciences Co., Ltd. ("Sinovac LS", previously known as Sinovac Research and Development Co., Ltd.), which will be funded by internal resources of the Group and result in a 15.03% equity interest in Sinovac LS. more info >> |
|
| Monday, November 30, 2020 |
|
|
Sino Biopharmaceutical Announces 2020 Third Quarterly Results |
| Sino Biopharmaceutical Limited ("Sino Biopharmaceutical" or the "Company", together with its subsidiaries, the "Group") (HKEX:1177), a leading and innovation-driven pharmaceutical conglomerate in the PRC, more info >> |
|
| Friday, August 28, 2020 |
|
|
Sino Biopharm Announces 2020 Interim Results |
| Sino Biopharmaceutical Limited ("Sino Biopharm" or the "Company", together with its subsidiaries, the "Group") (HKEX:1177), a leading, innovative research and development ("R&D") driven pharmaceutical conglomerate in the PRC, has announced its unaudited interim results for the six months ended 30 June 2020 (the "review period"). more info >> |
|
| Thursday, May 28, 2020 |
|
|
Sino Biopharmaceutical Announces 2020 First Quarterly Results |
| Sino Biopharmaceutical Limited ("Sino Biopharmaceutical" or the "Company", together with its subsidiaries, the "Group") (HKEX:1177), a leading, innovative research and development ("R&D") driven pharmaceutical conglomerate in the PRC, has announced its unaudited first quarterly results for the three months ended 31 March 2020 ("the review period"). more info >> |
|
| Tuesday, May 26, 2020 |
|
|
New Drug Application of Penpulimab Co-developed by Sino Biopharmaceutical and Akeso Accepted by the National Medical Products Administration |
| Sino Biopharmaceutical Limited (HKEX: 1177), a leading, innovative research and development ("R&D") driven pharmaceutical conglomerate in the PRC, has announced that the new drug application of the anti PD-1 monoclonal antibody drug more info >> |
|
| Tuesday, May 19, 2020 |
|
|
Results from Clinical Trials of Penpulimab in Combination with Anlotinib for 1L HCC Co-developed by Sino Biopharmaceutical and Akeso Accepted for Presentation at ASCO Annual Meeting |
| Sino Biopharmaceutical Limited (HKEX: 1177), a leading, innovative research and development ("R&D") driven pharmaceutical conglomerate in the PRC, has announced that the abstracts on phase II study on clinical efficacy and safety of Penpulimab more info >> |
|
| Monday, March 30, 2020 |
|
|
Sino Biopharm Announces 2019 Annual Results |
| Sino Biopharmaceutical Limited ("Sino Biopharm" or the "Company", together with its subsidiaries, the "Group") (HKEX: 1177), a leading, innovative research and development driven pharmaceutical conglomerate in the PRC, has announced its financial results for the year ended 31 December 2019 ("the year"). more info >> |
|
| Tuesday, January 21, 2020 |
|
|
Asia-Pacific has Record Year for Clinical Trials says Novotech CRO |
| Novotech CRO the largest biotech CRO in the Asia-Pacific said the region has had a record year for number of studies, experienced world-class sites and investigators, and patient enrolment. more info >> |
|
| Tuesday, November 26, 2019 |
|
|
Sino Biopharmaceutical Announces 2019 Third Quarterly Results |
| Sino Biopharmaceutical Limited ("Sino Biopharmaceutical" or the "Company", together with its subsidiaries, the "Group") (HKEX:1177), a leading and innovation-driven pharmaceutical conglomerate in the PRC, has announced its unaudited third quarterly results for the nine months ended 30 September 2019 ("the review period"). more info >> |
|
| Thursday, August 29, 2019 |
|
|
Sino Biopharmaceutical Announces 2019 Interim Results |
Sino Biopharmaceutical Limited ("Sino Biopharmaceutical" or the "Company", together with its subsidiaries, the "Group") (HKEX:1177), a leading and innovation-driven pharmaceutical conglomerate in the PRC, has announced today its unaudited interim results for the six months ended 30 June 2019 (the "review period").
more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
Open World and VerifyMe Sign Merger Agreement
Feb 12, 2026 21:00 HKT/SGT
|
|
|
U.S. Polo Assn. Unveils Experiential USPA Shop Flagship at the USPA National Polo Center
Feb 12, 2026 20:00 HKT/SGT
|
|
|
Radisson Highlights Developing Vein Model at O'Brien Gold Project with Implications for Future Growth and Mine Planning
Feb 12, 2026 19:59 HKT/SGT
|
|
|
Lockheed Martin and Fujitsu Formalize Industrial Collaboration for Japan Defense
Feb 12, 2026 19:59 JST
|
|
|
Meiji and Fujitsu launch world's first rRAFU(TM) pilot to assess future malnutrition and frailty risk
Feb 12, 2026 16:09 JST
|
|
|
Airwheel Announces Expanded Global Deployment of AI-Enabled Rideable Smart Electric Cabin Suitcase
Feb 12, 2026 11:30 HKT/SGT
|
|
|
Fujitsu Group starts manufacturing sovereign AI servers in Japan to enhance digital sovereignty
Feb 12, 2026 12:13 JST
|
|
|
Casa Minerals Inc Announces Closing of Oversubscribed Private Placement, and Retains European Marketing Firm for Investor Awareness Services
Feb 12, 2026 07:30 HKT/SGT
|
|
|
GTJAI Sponsored Axera's Listing on the Main Board of HKEX
Feb 11, 2026 19:40 HKT/SGT
|
|
|
Bioxytran Reports Positive Phase 2 Results Demonstrating Rapid Viral Clearance with ProLectin-MBioxytran
Feb 11, 2026 19:00 HKT/SGT
|
|
|
Focus Graphite Engages Dr. Reuter Investor Relations to Expand German and European Capital Markets Presence
Feb 11, 2026 18:29 HKT/SGT
|
|
|
CleverTap Recognized as a Leader in Latest Gartner Magic Quadrant for Personalization Engines
Feb 11, 2026 14:30 HKT/SGT
|
|
|
Premiere of Three-Row Highlander BEV in North America
Feb 11, 2026 14:25 JST
|
|
|
The 18th Annual Global CSR & ESG Summit & Awards 2026 Arrives in Bangkok -- Igniting Asia with AI, Energy & ESG Innovation on 23 April 2026
Feb 11, 2026 11:39 HKT/SGT
|
|
|
U.S. Marine Corps Selects GA-ASI for MUX TACAIR Collaborative Combat Aircraft Program
Feb 11, 2026 08:00 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
